TS-172 clinical trials
Also written TS-172.
How each study uses TS-172 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the TS-172 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- TS-172
- 6
Studies by the year they started
10 studies that test it; most in 2025 (7)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 7 |
Who runs them
Industry 10 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test TS-172, phase 3 first.
- Jul 2027A Long-term Study of TS-172 in Hyperphosphatemia Patients on HemodialysisPhase 3 · Taisho Pharmaceutical Co., Ltd.
Studies
Open first, then newest update. How each study uses TS-172 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- A Long-term Study of TS-172 in Hyperphosphatemia Patients on HemodialysisRecruitingPhase 3Taisho Pharmaceutical Co., Ltd.NCT07285304Written as TS-172
- A Pharmacokinetic Study of TS-172 in Patients With Hepatic ImpairmentCompletedPhase 1Taisho Pharmaceutical Co., Ltd.NCT07231029Written as TS-172
- A Pharmacodynamic Study of TS-172 in Healthy Adult Male SubjectsCompletedPhase 1Taisho Pharmaceutical Co., Ltd.NCT07084961Written as TS-172
- A Phase 2 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate BindersCompletedPhase 2Taisho Pharmaceutical Co., Ltd.NCT06745518Written as TS-172
- A QT/QTc Evaluation Study of TS-172 in Healthy Adult SubjectsCompletedPhase 1Taisho Pharmaceutical Co., Ltd.NCT06837155Written as TS-172 20 mg
- A Drug-drug Interaction Study With TS-172 in Healthy Adult Male SubjectsCompletedPhase 1Taisho Pharmaceutical Co., Ltd.NCT06837142Written as Triazolam and TS-172
- An Open-label Pharmacokinetic Study of TS-172 in Patients on HemodialysisCompletedPhase 1Taisho Pharmaceutical Co., Ltd.NCT06849778Written as TS-172
- A Phase I Study of TS-172 in Healthy Adult Subjects (Single and Multiple Doses)CompletedPhase 1Taisho Pharmaceutical Co., Ltd.NCT04979572Written as TS-172
- A Phase 2 Dose-finding Study of TS-172 in Hyperphosphatemia Patients on HemodialysisCompletedPhase 2Taisho Pharmaceutical Co., Ltd.NCT05699239Written as TS-172 10mg bid
- A Mass Balance Study of TS-172 in Healthy Adult SubjectsCompletedPhase 1Taisho Pharmaceutical Co., Ltd.NCT06596356Written as [14C] TS-172